Martyn Webb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Martyn Webb has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Rachel Hurst
Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK
3 shared publications- Shea P. Connell
Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
3 shared publications Antoinette S. Perry
School of Biology and Environmental Science, University College Dublin, Dublin, Ireland
2 shared publicationsColin S. Cooper
Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK
2 shared publications- Daniel S. Brewer
Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK
2 shared publications - Ian Geoffrey Mills
Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK
2 shared publications
Latest Publications
- Open Access
- 9 March 2020
- Published by Wiley in The Prostate
- Vol. 80 (7) , 547-558
Development of a multivariable risk model integrating urinary cell DNA methylation and cell‐free RNA data for the detection of significant prostate cancer
Background: Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically implementable tools able to precisely and noninvasively identify patients that can either be safely removed from treatment pathways or those requiring further follow up. Our objectives were to develop a multivariable risk prediction model through the integration of clinical, urine‐derived cell‐free messenger RNA (cf‐RNA) and urine cell DNA methylation data capable of noninvasively detecting significant prostate cancer in biopsy naïve patients.Methods: Post‐digital rectal examination urine samples previously analyzed separately for both cellular methylation and cf‐RNA expression within the Movember GAP1 urine biomarker cohort were selected for a fully integrated analysis (n = 207). A robust feature selection framework, based on bootstrap resampling and permutation, was utilized to find the optimal combination of clinical and urinary markers in a random forest model, deemed ExoMeth. Out‐of‐bag predictions from ExoMeth were used for diagnostic evaluation in men with a clinical suspicion of prostate cancer (PSA ≥ 4 ng/mL, adverse digital rectal examination, age, or lower urinary tract symptoms).Results: As ExoMeth risk score (range, 0‐1) increased, the likelihood of high‐grade disease being detected on biopsy was significantly greater (odds ratio = 2.04 per 0.1 ExoMeth increase, 95% confidence interval [CI]: 1.78‐2.35). On an initial TRUS biopsy, ExoMeth accurately predicted the presence of Gleason score ≥3 + 4, area under the receiver‐operator characteristic curve (AUC) = 0.89 (95% CI: 0.84‐0.93) and was additionally capable of detecting any cancer on biopsy, AUC = 0.91 (95% CI: 0.87‐0.95). Application of ExoMeth provided a net benefit over current standards of care and has the potential to reduce unnecessary biopsies by 66% when a risk threshold of 0.25 is accepted.Conclusion: Integration of urinary biomarkers across multiple assay methods has greater diagnostic ability than either method in isolation, providing superior predictive ability of biopsy outcomes. ExoMeth represents a more holistic view of urinary biomarkers and has the potential to result in substantial changes to how patients suspected of harboring prostate cancer are diagnosed.
- 9 March 2020
- Published by Wiley in The Prostate
- Vol. 80 (7) , 547-558
Open AccessDevelopment of a multivariable risk model integrating urinary cell DNA methylation and cell‐free RNA data for the detection of significant prostate cancer
Background: Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically implementable tools able to precisely and noninvasively identify patients that can either be safely removed from treatment pathways or those requiring further follow up. Our objectives were to develop a multivariable risk prediction model through the integration of clinical, urine‐derived cell‐free messenger RNA (cf‐RNA) and urine cell DNA methylation data capable of noninvasively detecting significant prostate cancer in biopsy naïve patients.Methods: Post‐digital rectal examination urine samples previously analyzed separately for both cellular methylation and cf‐RNA expression within the Movember GAP1 urine biomarker cohort were selected for a fully integrated analysis (n = 207). A robust feature selection framework, based on bootstrap resampling and permutation, was utilized to find the optimal combination of clinical and urinary markers in a random forest model, deemed ExoMeth. Out‐of‐bag predictions from ExoMeth were used for diagnostic evaluation in men with a clinical suspicion of prostate cancer (PSA ≥ 4 ng/mL, adverse digital rectal examination, age, or lower urinary tract symptoms).Results: As ExoMeth risk score (range, 0‐1) increased, the likelihood of high‐grade disease being detected on biopsy was significantly greater (odds ratio = 2.04 per 0.1 ExoMeth increase, 95% confidence interval [CI]: 1.78‐2.35). On an initial TRUS biopsy, ExoMeth accurately predicted the presence of Gleason score ≥3 + 4, area under the receiver‐operator characteristic curve (AUC) = 0.89 (95% CI: 0.84‐0.93) and was additionally capable of detecting any cancer on biopsy, AUC = 0.91 (95% CI: 0.87‐0.95). Application of ExoMeth provided a net benefit over current standards of care and has the potential to reduce unnecessary biopsies by 66% when a risk threshold of 0.25 is accepted.Conclusion: Integration of urinary biomarkers across multiple assay methods has greater diagnostic ability than either method in isolation, providing superior predictive ability of biopsy outcomes. ExoMeth represents a more holistic view of urinary biomarkers and has the potential to result in substantial changes to how patients suspected of harboring prostate cancer are diagnosed.
- Open Access
- 29 November 2019
- Published by Taylor & Francis in BioTechniques
- Vol. 68 (2) , 65-71
Methodology for the At-home Collection of Urine Samples for Prostate Cancer Detection
Urine from patients with prostate cancer (PCa) contains gene transcripts that have been used for PCa diagnosis and prognosis. Historically, patient urine samples have been collected after a digital... METHOD SUMMARY The use of a commercial preservative allowed samples to be maintained at room temperature without loss of RNA quality. Harvest of cell-free RNA using a novel high-volume vacuum extra...
- 29 November 2019
- Published by Taylor & Francis in BioTechniques
- Vol. 68 (2) , 65-71
Open AccessMethodology for the At-home Collection of Urine Samples for Prostate Cancer Detection
Urine from patients with prostate cancer (PCa) contains gene transcripts that have been used for PCa diagnosis and prognosis. Historically, patient urine samples have been collected after a digital... METHOD SUMMARY The use of a commercial preservative allowed samples to be maintained at room temperature without loss of RNA quality. Harvest of cell-free RNA using a novel high-volume vacuum extra...
- Open Access
- 20 May 2019
- Published by Wiley in BJU International
- Vol. 124 (4) , 609-620
A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
Objectives: To develop a risk classifier using urine‐derived extracellular vesicle ( EV )‐ RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance ( AS ). Patients and Methods: Post‐digital rectal examination urine‐derived EV ‐ RNA expression profiles ( n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO ‐based continuation ratio model was built to generate four prostate urine risk ( PUR ) signatures for predicting the probability of normal tissue ( PUR ‐1), D'Amico low‐risk ( PUR ‐2), intermediate‐risk ( PUR ‐3), and high‐risk ( PUR ‐4) prostate cancer. This model was applied to a test cohort ( n = 177) for diagnostic evaluation, and to an AS sub‐cohort ( n = 87) for prognostic evaluation. Results: Each PUR signature was significantly associated with its corresponding clinical category ( P < 0.001). PUR ‐4 status predicted the presence of clinically significant intermediate‐ or high‐risk disease (area under the curve = 0.77, 95% confidence interval [ CI ] 0.70–0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub‐cohort ( n = 87), groups defined by PUR status and proportion of PUR ‐4 had a significant association with time to progression (interquartile range hazard ratio [ HR ] 2.86, 95% CI 1.83–4.47; P < 0.001). PUR ‐4, when used continuously, dichotomized patient groups with differential progression rates of 10% and 60% 5 years after urine collection ( HR 8.23, 95% CI 3.26–20.81; P < 0.001). Conclusion: Urine‐derived EV‐ RNA can provide diagnostic information on aggressive prostate cancer prior to biopsy, and prognostic information for men on AS . PUR represents a new and versatile biomarker that could result in substantial alterations to current treatment of patients with prostate cancer.
- 20 May 2019
- Published by Wiley in BJU International
- Vol. 124 (4) , 609-620
Open AccessA four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
Objectives: To develop a risk classifier using urine‐derived extracellular vesicle ( EV )‐ RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance ( AS ). Patients and Methods: Post‐digital rectal examination urine‐derived EV ‐ RNA expression profiles ( n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO ‐based continuation ratio model was built to generate four prostate urine risk ( PUR ) signatures for predicting the probability of normal tissue ( PUR ‐1), D'Amico low‐risk ( PUR ‐2), intermediate‐risk ( PUR ‐3), and high‐risk ( PUR ‐4) prostate cancer. This model was applied to a test cohort ( n = 177) for diagnostic evaluation, and to an AS sub‐cohort ( n = 87) for prognostic evaluation. Results: Each PUR signature was significantly associated with its corresponding clinical category ( P < 0.001). PUR ‐4 status predicted the presence of clinically significant intermediate‐ or high‐risk disease (area under the curve = 0.77, 95% confidence interval [ CI ] 0.70–0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub‐cohort ( n = 87), groups defined by PUR status and proportion of PUR ‐4 had a significant association with time to progression (interquartile range hazard ratio [ HR ] 2.86, 95% CI 1.83–4.47; P < 0.001). PUR ‐4, when used continuously, dichotomized patient groups with differential progression rates of 10% and 60% 5 years after urine collection ( HR 8.23, 95% CI 3.26–20.81; P < 0.001). Conclusion: Urine‐derived EV‐ RNA can provide diagnostic information on aggressive prostate cancer prior to biopsy, and prognostic information for men on AS . PUR represents a new and versatile biomarker that could result in substantial alterations to current treatment of patients with prostate cancer.